Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2026 Opus Genetics, Inc. has completed patient enrollment in its registrational Phase 3...
RMAT
Advertisement
Opus Genetics Secures FDA Alignment for Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., July 6, 2026 Opus Genetics announced that the U.S. Food and Drug Administration (FDA) has...
Mesoblast Receives FDA BLA Filing Number for Rexlemestrocel-L
New York, USA & Melbourne, Australia, July 1, 2026 Mesoblast Limited announced that the U.S. Food and Drug Administration...
Opus Genetics Enters FDA RDEP Program for OPGx-LCA5
RESEARCH TRIANGLE PARK, N.C. – May 4, 2026 Opus Genetics Inc. has announced that its investigational gene therapy OPGx-LCA5...
Intellia Completes Phase 3 Enrollment for HAE Gene Therapy
September 18, 2025 — Cambridge, Massachusetts Intellia has completed enrollment in the global Phase 3 HAELO trial of lonvoguran...
Advertisement
